DY131
Modify Date: 2024-01-07 18:19:49
DY131 structure
|
Common Name | DY131 | ||
|---|---|---|---|---|
| CAS Number | 95167-41-2 | Molecular Weight | 311.378 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | N/A | |
| Molecular Formula | C18H21N3O2 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | N/A | |
Use of DY131DY131(GSK 9089) is a novel selective agonist of ERRβ and ERRγ; displays minimal activity at ERRα, ERα and ERβ at concentrations up to 30 μM.IC50 value:Target: ERRβ/γDY131, a selective ERRγ agonist, could potentiate the ERRγ-induced growth inhibition in LNCaP- ERRγ and DU145- ERRγ cells in a dose-dependent manner compared with respective parental cells. DY131 inhibited the growth of the ERα-positive endometrial cancer cells but promoted that of the ERα-negative cancer cells. DY131 had no effect on the structurally related receptors ERRα or the estrogen receptors alpha and beta (ERalpha/beta). DY131 appears to inhibit Smo signaling through a common binding site shared by previously reported Smo agonists and antagonists. |
| Name | DY131 |
|---|---|
| Synonym | More Synonyms |
| Description | DY131(GSK 9089) is a novel selective agonist of ERRβ and ERRγ; displays minimal activity at ERRα, ERα and ERβ at concentrations up to 30 μM.IC50 value:Target: ERRβ/γDY131, a selective ERRγ agonist, could potentiate the ERRγ-induced growth inhibition in LNCaP- ERRγ and DU145- ERRγ cells in a dose-dependent manner compared with respective parental cells. DY131 inhibited the growth of the ERα-positive endometrial cancer cells but promoted that of the ERα-negative cancer cells. DY131 had no effect on the structurally related receptors ERRα or the estrogen receptors alpha and beta (ERalpha/beta). DY131 appears to inhibit Smo signaling through a common binding site shared by previously reported Smo agonists and antagonists. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Molecular Formula | C18H21N3O2 |
| Molecular Weight | 311.378 |
| Exact Mass | 311.163391 |
| PSA | 64.93000 |
| LogP | 3.17 |
| Index of Refraction | 1.574 |
| Storage condition | 2-8°C |
| Hazard Codes | Xi: Irritant; |
|---|---|
| Risk Phrases | 36/37/38 |
| Safety Phrases | 26-36 |
| HS Code | 2928000090 |
|
~66%
DY131 CAS#:95167-41-2 |
| Literature: Forman, Barry; Yu, Donna Patent: US2006/189825 A1, 2006 ; Location in patent: Page/Page column 7; 12; Sheet 3/7 ; US 20060189825 A1 |
|
~%
DY131 CAS#:95167-41-2 |
| Literature: Bioorganic and Medicinal Chemistry Letters, , vol. 15, # 5 p. 1311 - 1313 |
|
~%
DY131 CAS#:95167-41-2 |
| Literature: Bioorganic and Medicinal Chemistry Letters, , vol. 15, # 5 p. 1311 - 1313 |
|
~%
DY131 CAS#:95167-41-2 |
| Literature: Journal of Medicinal Chemistry, , vol. 48, # 9 p. 3107 - 3109 |
| HS Code | 2928000090 |
|---|---|
| Summary | 2928000090 other organic derivatives of hydrazine or of hydroxylamine VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:20.0% |
| Benzoic acid, 4-hydroxy-, 2-[(1E)-[4-(diethylamino)phenyl]methylene]hydrazide |
| N'-{(E)-[4-(diethylamino)phenyl]methylidene}-4-hydroxybenzohydrazide |
| N'-{(E)-[4-(Diethylamino)phenyl]methylene}-4-hydroxybenzohydrazide |
| Benzoic acid, 4-hydroxy-, [[4-(diethylamino)phenyl]methylene]hydrazide (9CI) |
| N-(4-(Diethylaminobenzylidenyl)-N'-(4-hydroxybenzoyl)-hydrazine |
| GSK 9089 |